Table 4. Univariate and multivariate Cox regression analysis of prognostic factors of overall survival.
| Variables | Univariate analysis |
Multivariate analysis* |
||
|---|---|---|---|---|
| HR 95%CI | P-value | HR 95%CI | P-value | |
| Age (≥81 years) | 2.52 (1.54–4.13) | <0.001 | 2.69 (1.39–5.23) | 0.003 |
| Male gender | 0.94 (0.61–1.46) | 0.788 | ||
| Performance status 2–4 | 4.36 (2.49–7.65) | <0.001 | 1.27 (0.69–2.31) | 0.433 |
| aaIPI 2 or 3 | 4.49 (2.66–7.60) | <0.001 | 3.08 (1.26–7.49) | 0.013 |
| BM involvement | 2.02 (1.21–3.39) | 0.008 | 1.97 (1.07–3.61) | 0.029 |
| Stage 3–4 | 3.40 (2.01–5.78) | <0.001 | 1.17 (0.53–2.58) | 0.707 |
| With B symptoms | 1.54 (0.97–2.44) | 0.069 | 1.09 (0.65–1.84) | 0.745 |
| Abnormal LDH level | 2.52 (1.46–4.37) | 0.001 | 0.97 (0.48–1.94) | 0.922 |
| Abnormal B2M level | 2.49 (1.59–3.89) | <0.001 | 1.49 (0.87–2.58) | 0.145 |
| Low albumin level | 2.23 (1.42–3.48) | <0.001 | 1.26 (0.74–2.15) | 0.402 |
| Renal function impairment | 1.72 (1.09–2.71) | 0.019 | 0.85 (0.49–1.48) | 0.562 |
| Symptoms of TLS at diagnosis | 3.69 (1.74–7.83) | 0.001 | 2.22 (0.82–6.03) | 0.118 |
| At least 1 comorbidity | 1.21 (0.73–2.01) | 0.456 | ||
| CCI ≥ 1 | 1.42 (0.92–2.20) | 0.115 | ||
*Factors with P-value less than 0.1 in the univariate analysis were entered into the multivariate analysis. aaIPI, age-adjusted international prognostic index; B2M, beta2-microglobulin; CCI, Charlson comorbidity index; HR, hazard ratio; LDH, lactate dehydrogenase; TLS, tumour lysis syndrome.